EGFR VIII

CI-VAR-00004666Explore in graph →NP_005219.2:p.Val30_Arg297delinsGlyNM_005228.3:c.89_881delCIViC 312

Curated evidence

Evidence by cancer (9 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–9 of 9 evidence items across 5 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Glioblastoma5
EGFR VIII	Afatinib	Predictive	D	Supports Sensitivity Response	4	submitted	EID8191 Patient-derived GBM brain tumour stem cells (BTSCs) were used to test the efficacy of the EGFR inhibitor afatinib in vitro and in vivo. Afatinib inhibited the growth and sphere-forming ability of BTSC… (full text at CIViC) PMID 32226941 · Jensen et al., 2020 · Open in CIViC	civic
EGFR VIII	Afatinib + PacritinibCombination	Predictive	D	Supports Sensitivity Response	3	submitted	EID8192 Patient-derived GBM brain tumour stem cells (BTSCs) were used to test the efficacy of the EGFR inhibitor afatinib and JAK2 inhibitor pacritinib in vitro and in vivo. Combination treatment with subopti… (full text at CIViC) PMID 32226941 · Jensen et al., 2020 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Head and Neck Squamous Cell Carcinoma1
EGFR VIII	Cetuximab + DocetaxelCombination	Predictive	B	Supports Resistance	2	accepted	EID848 47 HNSCC patients treated with cetuximab/docetaxel were retrospectively analyzed for EGFRvIII, EGFR, and AREG expression by IHC. 17% of cases expressed high levels of EGFRvIII. High vIII expression wa… (full text at CIViC) PMID 21653686 · Tinhofer et al., 2011 · Open in CIViC	civic

High-Grade Glioma, NOS1
EGFR VIII	Erlotinib	Predictive	D	Supports Sensitivity Response	3	accepted	EID4500 In an in vitro study, a Ba/F3 cell line expressing EGFR vIII demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Variant function was assessed… (full text at CIViC) PMID 17177598 · Lee et al., 2006 · Open in CIViC	civic

Malignant Glioma1
EGFR Amplification OR EGFR VIII	Osimertinib	Predictive	C	Supports Sensitivity Response	2	submitted	EID12694 In a single-center retrospective review of recurrent malignant gliomas with EGFR alterations (n = 6, 2 GBM), osimertinib showed a manageable safety profile with thrombocytopenia in 2 patients (grade 2… (full text at CIViC) PMID 35601813 · Abousaud et al., 2021 · Open in CIViC	civic

Brain Glioma1unmapped disease
EGFR VIII	Nimotuzumab	Predictive	D	Supports Sensitivity Response	1	accepted	EID1017 Two human glioma cell lines (U87MG or LNZ308) overexpressing either wild-type (wt) EGFR or EGFRvIII were treated with nimotuzumab, temozolomide, or both in vitro. Anti-tumor effects of nimotuzumab wer… (full text at CIViC) PMID 26778701 · Nitta et al., 2016 · Open in CIViC	civic